Biodesix, Inc. – NASDAQ:BDSX
Biodesix stock price today
$0.419
-1.06
-71.7%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 12 minutes
Biodesix stock price monthly change
-12.43%
month
Biodesix stock price quarterly change
-12.43%
quarter
Biodesix stock price yearly change
-18.68%
year
Biodesix key metrics
Market Cap | 218.20M |
Enterprise value | 82.98M |
P/E | -1.12 |
EV/Sales | 2.17 |
EV/EBITDA | -1.61 |
Price/Sales | 2.46 |
Price/Book | 4.57 |
PEG ratio | -0.58 |
EPS | -0.54 |
Revenue | 54.84M |
EBITDA | -31.85M |
Income | -47.05M |
Revenue Q/Q | 63.62% |
Revenue Y/Y | 34.69% |
Profit margin | -171.27% |
Oper. margin | -132.17% |
Gross margin | 62.96% |
EBIT margin | -132.17% |
EBITDA margin | -58.07% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiodesix stock price history
Biodesix stock forecast
Biodesix financial statements
| Jun 2023 | 11.87M | -13.35M | -112.5% |
|---|---|---|---|
| Sep 2023 | 13.49M | -10.94M | -81.16% |
| Dec 2023 | 14.66M | -9.13M | -62.31% |
| Mar 2024 | 14.81M | -13.61M | -91.87% |
| Mar 2024 | 14.81M | -13.61M | -91.87% |
|---|---|---|---|
| Sep 2025 | 20.20M | -5.95M | -29.48% |
| Oct 2025 | 21.38M | -5.16M | -24.14% |
| Dec 2025 | 22.52M | -4.41M | -19.62% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 77623000 | 84.61M | 109.01% |
|---|---|---|---|
| Sep 2023 | 86786000 | 88.23M | 101.67% |
| Dec 2023 | 99096000 | 94.51M | 95.38% |
| Mar 2024 | 87201000 | 92.70M | 106.31% |
| Jun 2023 | 937K | -6.47M | -2.33M |
|---|---|---|---|
| Sep 2023 | -3.83M | -5.88M | 12.15M |
| Dec 2023 | -11.45M | -3.00M | 20.89M |
| Mar 2024 | -15.32M | -273K | 809K |
Biodesix alternative data
| Aug 2023 | 245 |
|---|---|
| Sep 2023 | 245 |
| Oct 2023 | 245 |
| Nov 2023 | 245 |
| Dec 2023 | 245 |
| Jan 2024 | 245 |
| Feb 2024 | 245 |
| Mar 2024 | 217 |
| Apr 2024 | 217 |
| May 2024 | 217 |
| Jun 2024 | 217 |
| Jul 2024 | 217 |
Biodesix other data
31.24%
-8.45%
of BDSX is owned by hedge funds
18
-14
13.15M
-2.90M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 50840 |
| May 2024 | 0 | 5890 |
| Aug 2024 | 0 | 5824 |
| Nov 2024 | 643953 | 5803 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SCHULER JACK W director, 10 percent owner: | Common Stock | 100,000 | $1.23 | $122,800 | ||
Purchase | KENNEDY LAWRENCE T. JR director, 10 percent owner: | Common Stock | 35,000 | $1.16 | $40,565 | ||
Purchase | SCHULER JACK W director, 10 percent owner: | Common Stock | 200,000 | $1.17 | $234,000 | ||
Sale | VAZQUEZ CHRIS officer: Chief Accounting Officer | Common Stock | 98 | $1.4 | $137 | ||
Sale | PESTANO GARY ANTHONY officer: Chief Development Offi.. | Common Stock | 207 | $1.4 | $290 | ||
Sale | O'KANE KIERAN officer: Chief Commercial Officer | Common Stock | 224 | $1.4 | $314 | ||
Sale | HUTTON SCOTT director, officer.. | Common Stock | 1,813 | $1.4 | $2,540 | ||
Sale | COWIE ROBIN HARPER officer: CFO, Sec.. | Common Stock | 471 | $1.4 | $660 | ||
Sale | VAZQUEZ CHRIS officer: Chief Accounting Officer | Common Stock | 105 | $1.39 | $146 | ||
Sale | PESTANO GARY ANTHONY officer: Chief Development Offi.. | Common Stock | 220 | $1.39 | $306 |
| Patent |
|---|
Application Filling date: 14 Feb 2022 Issue date: 18 Aug 2022 |
Application INTERPRETATION OF MACHINE LEARNING CLASSIFICATIONS IN CLINICAL DIAGNOSTICS USING SHAPELY VALUES AND USES THEREOF Filling date: 28 Jun 2021 Issue date: 16 Jun 2022 |
Application Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings Filling date: 10 Jun 2021 Issue date: 16 Jun 2022 |
Application Filling date: 9 Sep 2021 Issue date: 2 Jun 2022 |
Application Classifier Generation Methods and Predictive Test for Ovarian Cancer Patient Prognosis Under Platinum Chemotherapy Filling date: 10 Mar 2017 Issue date: 7 Apr 2022 |
Application METHOD FOR IDENTIFICATION OF CANCER PATIENTS WITH DURABLE BENEFIT FROM IMMUNOTEHRAPY IN OVERALL POOR PROGNOSIS SUBGROUPS Filling date: 6 Oct 2021 Issue date: 27 Jan 2022 |
Grant Filling date: 18 Aug 2017 Issue date: 7 Dec 2021 |
Grant Utility: Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups Filling date: 5 Jan 2018 Issue date: 19 Oct 2021 |
Application Filling date: 19 Nov 2020 Issue date: 14 Oct 2021 |
Application Filling date: 13 Oct 2020 Issue date: 16 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Scott Hutton (1972) Pres, Chief Executive Officer & Director | $531,880 |
| Ms. Robin Harper Cowie (1980) Chief Financial Officer, Sec. & Treasurer | $375,240 |
Mr. Kieran O'Kane (1977) Chief Commercial Officer | $310,060 |
-
What's the price of Biodesix stock today?
One share of Biodesix stock can currently be purchased for approximately $0.42.
-
When is Biodesix's next earnings date?
Unfortunately, Biodesix's (BDSX) next earnings date is currently unknown.
-
Does Biodesix pay dividends?
No, Biodesix does not pay dividends.
-
How much money does Biodesix make?
Biodesix has a market capitalization of 218.20M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 28.46% to 49.09M US dollars.
-
What is Biodesix's stock symbol?
Biodesix, Inc. is traded on the NASDAQ under the ticker symbol "BDSX".
-
What is Biodesix's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Biodesix?
Shares of Biodesix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Biodesix's key executives?
Biodesix's management team includes the following people:
- Mr. Scott Hutton Pres, Chief Executive Officer & Director(age: 53, pay: $531,880)
- Ms. Robin Harper Cowie Chief Financial Officer, Sec. & Treasurer(age: 45, pay: $375,240)
- Mr. Kieran O'Kane Chief Commercial Officer(age: 48, pay: $310,060)
-
How many employees does Biodesix have?
As Jul 2024, Biodesix employs 217 workers.
-
When Biodesix went public?
Biodesix, Inc. is publicly traded company for more then 4 years since IPO on 28 Oct 2020.
-
What is Biodesix's official website?
The official website for Biodesix is biodesix.com.
-
Where are Biodesix's headquarters?
Biodesix is headquartered at 2970 Wilderness Place, Boulder, CO.
-
How can i contact Biodesix?
Biodesix's mailing address is 2970 Wilderness Place, Boulder, CO and company can be reached via phone at +30 34170500.
Biodesix company profile:
Biodesix, Inc.
biodesix.comExchange:
NASDAQ
Full time employees:
217
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
2970 Wilderness Place
Boulder, CO 80301
Boulder, CO 80301
CIK: 0001439725
ISIN: US09075X1081
CUSIP: 09075X108
